INMB (INmune Bio, Inc.) Stock Financials & Earnings | Market Cap Arena

INMB (INmune Bio, Inc.) Stock Financials & Earnings | Market Cap Arena

INMBINmune Bio, Inc.

Mkt Cap$35M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$50,000

Net Income (TTM)-$50M

EPS (TTM)-$2.13

Free Cash Flow (TTM)-$32M

Gross Margin44.0%

Op. Margin-102752.0%

Net Margin-99774.0%

FCF Margin-63100.0%

P/S Ratio (TTM)707.2x

P/E Ratio (TTM)—

YoY Rev Growth+19.0%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$97K	$97K	-$6M
Q1 23	$38K	$38K	-$6M
Q2 23	$46K	$46K	-$6M
Q3 23	$43K	$43K	-$9M
Q4 23	$28K	$28K	-$8M
Q1 24	$14K	$14K	-$11M
Q2 24	$0	$0	-$10M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$9M
Q1 25	$50K	$50K	-$10M
Q2 25	$0	$0	-$25M
Q3 25	$0	-$28K	-$7M

Valuation

Quarter	P/S	P/E
Q4 22	94.5x	—
Q1 23	142.0x	—
Q2 23	126.7x	—
Q3 23	157.8x	—
Q4 23	228.1x	—
Q1 24	269.9x	—
Q2 24	416.0x	—
Q3 24	841.9x	—
Q4 24	2525.6x	—
Q1 25	707.2x	—
Q2 25	707.2x	—
Q3 25	707.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$6M	-$6M
Q1 23	-$1M	-$1M
Q2 23	-$3M	-$3M
Q3 23	-$4M	-$4M
Q4 23	-$3M	-$3M
Q1 24	-$7M	-$7M
Q2 24	-$8M	-$8M
Q3 24	-$7M	-$7M
Q4 24	-$11M	-$11M
Q1 25	-$7M	-$7M
Q2 25	-$7M	-$8M
Q3 25	-$5M	-$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$706K
Q3 25	$193K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-40.5%	-37.6%
Q1 23	-76.7%	-2.7%
Q2 23	+187.5%	+0.8%
Q3 23	-56.1%	+13.7%
Q4 23	-71.1%	+46.5%
Q1 24	-63.2%	+70.7%
Q2 24	-100.0%	+52.8%
Q3 24	-100.0%	+43.3%
Q4 24	-100.0%	+12.6%
Q1 25	+257.1%	-9.8%
Q2 25	—	+149.1%
Q3 25	—	-39.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$2M	1843.3%
Q1 23	$2M	4571.1%
Q2 23	$2M	4050.0%
Q3 23	$2M	4393.0%
Q4 23	$2M	6710.7%
Q1 24	$2M	12707.1%
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	4152.0%
Q2 25	$2M	—
Q3 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$3M	$2M	$47K	—
Q1 23	$4M	$2M	$43K	—
Q2 23	$4M	$2M	—	—
Q3 23	$6M	$3M	—	—
Q4 23	$6M	$2M	—	—
Q1 24	$9M	$2M	—	—
Q2 24	$7M	$3M	$41K	—
Q3 24	$10M	—	—	$2M
Q4 24	$7M	$2M	—	—
Q1 25	$8M	$2M	—	—
Q2 25	$6M	$2M	—	—
Q3 25	$5M	—	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$52M	$0	$52M
Q1 23	$51M	$0	$51M
Q2 23	$48M	$0	$48M
Q3 23	$42M	$0	$42M
Q4 23	$36M	$0	$36M
Q1 24	$26M	$0	$26M
Q2 24	$31M	$0	$31M
Q3 24	$34M	$0	$34M
Q4 24	$21M	$0	$21M
Q1 25	$19M	$0	$19M
Q2 25	$33M	$0	$33M
Q3 25	$28M	$0	$28M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	18M	-0.1%
Q1 23	18M	+0.1%
Q2 23	18M	+0.0%
Q3 23	18M	+0.3%
Q4 23	18M	-0.3%
Q1 24	18M	+0.4%
Q2 24	19M	+7.1%
Q3 24	20M	+4.6%
Q4 24	22M	+10.4%
Q1 25	22M	+1.0%
Q2 25	23M	+3.6%
Q3 25	27M	+14.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	$0	3
FY 19	$0	4
FY 20	$2K	5
FY 21	$18K	10
FY 22	$37K	10
FY 23	$14K	11
FY 24	$1K	13